Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall …

Aug 4, 2023 · For the quarter ended June 2023, Travere Therapeutics (TVTX) reported revenue of $59.7 million, up 10.2% over the same period last year. EPS came in at -$1.13, compared …

2%
OFF

Travere (TVTX) Q2 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Aug 4, 2023 · For the quarter ended June 2023, Travere Therapeutics (TVTX) reported revenue of $59.7 million, up 10.2% over the same period last year. EPS came in at -$1.13, compared …

nasdaq.com

4%
OFF

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

2 weeks from now

Aug 1, 2024 · For the quarter ended June 2024, Travere Therapeutics (TVTX) reported revenue of $54.12 million, down 9.4% over the same period last year. EPS came in at -$0.90, …

nasdaq.com

6%
OFF

Travere Therapeutics Past Earnings Performance - Simply Wall St

2 weeks from now

Oct 31, 2024 · Travere Therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 19.3% annually. ... Unable to …

simplywall.st

4%
OFF

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

2 weeks from now

Aug 1, 2024 · For the quarter ended June 2024, Travere Therapeutics (TVTX Quick Quote TVTX - Free Report) reported revenue of $54.12 million, down 9.4% over the same period last …

zacks.com

$0.70
OFF

Travere Therapeutics (TVTX) Earnings Date And Reports 2025

2 weeks from now

In the previous quarter, Travere Therapeutics (NASDAQ:TVTX) reported ($0.70) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.71) by $0.01. Learn more on …

marketbeat.com

7%
OFF

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Nov 7, 2023 · Travere Therapeutics (TVTX) reported $37.1 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 30.7%.

nasdaq.com

5%
OFF

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX) reported $62.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 69.5%. EPS of -$0.70 for …

nasdaq.com

FAQs about Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall … Coupon?

How did Travere perform in the just reported quarter?

Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Tiopronin products / Thiola: $26.05 million compared to the $21.63 million average estimate based on six analysts. The reported number represents a change of +2.5% year over year. ...

How much did Travere Therapeutics earn in quarter 2023?

Travere Therapeutics last announced its quarterly earnings results on August 3rd, 2023. The reported ($1.13) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.03. The firm earned $59.70 million during the quarter, compared to analyst estimates of $53.93 million. ...

How much money does Travere Therapeutics make a year?

Travere Therapeutics (NASDAQ:TVTX) has a recorded annual revenue of $212.02 million. How much profit does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded net income of -$278.48 million. TVTX has generated -$4.52 earnings per share over the last four quarters. ...

When is Travere Therapeutics's earnings conference call?

Travere Therapeutics will be holding an earnings conference call on Tuesday, November 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call.. When is Travere Therapeutics's earnings date? ...

Is Travere (Travere) a good stock to buy?

The reported number represents a year-over-year change of -27.8%. Shares of Travere have returned +20.2% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. ...